ALNY vs. BMRN, RPRX, UTHR, IONS, GMAB, TEVA, VTRS, BGNE, KRTX, and RDY
Should you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Royalty Pharma (RPRX), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Viatris (VTRS), BeiGene (BGNE), Karuna Therapeutics (KRTX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.8% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
BioMarin Pharmaceutical currently has a consensus price target of $107.50, indicating a potential upside of 32.86%. Alnylam Pharmaceuticals has a consensus price target of $215.88, indicating a potential upside of 50.63%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.
BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
BioMarin Pharmaceutical has a net margin of 8.31% compared to BioMarin Pharmaceutical's net margin of -24.08%. Alnylam Pharmaceuticals' return on equity of 5.39% beat BioMarin Pharmaceutical's return on equity.
BioMarin Pharmaceutical received 448 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.10% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.76% of users gave BioMarin Pharmaceutical an outperform vote.
BioMarin Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
In the previous week, BioMarin Pharmaceutical had 35 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 48 mentions for BioMarin Pharmaceutical and 13 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.50 beat Alnylam Pharmaceuticals' score of 0.39 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Summary
BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Alnylam Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alnylam Pharmaceuticals Competitors List
Related Companies and Tools
